prmaconsulting™
Pricing, reimbursement and market access consulting

Publications

Sykes D, Castro R, Espuna Pons M, Hampel C, Hunskaar S, Papanicolaou S, Quail D, Samsioe G, Voss S, Wagg A, Monz B.

Characteristics of female outpatients with urinary incontinence participating in a 6-month observational study in 14 European countries. Maturitas 2005, 52(S2):3-12.

Papanicolaou S, Sykes D, Mossialos E A.

The EMEA and the Evaluation of Health-Related Quality of Life in Drug Regulatory Process. Int J Technology Assessment in Health Care, (2004), 20:311-324.

Papanicolaou S, Hunskaar S, Lose G, Sykes D.

Assessment of bothersomeness and impact on quality of life of urinary incontinence in women in France, Germany, Spain and the UK. BJU International (2005), 96:831-838.

Papanicolaou S, Espuna Pons M, Hampel C, Monz B, Quail D, Graf von der Schulenburg M, Wagg A, Sykes D.

Medical resource utilisation and cost of care for women seeking treatment for urinary incontinence in an outpatient setting. Examples from three countries participating in the PURE study. Maturitas 2005, 52(S2):3-12.

Papanicolaou S, Wagg A, Espuna M, Monz B, Sykes D.

Medical resource utilisation and cost of care for women seeking treatment for urinary incontinence in an outpatient setting. Examples from three countries participating in the PURE study. Maturitas 2005 Nov 30; 52 Suppl 2:S35-47.

Papanicolaou S, Lose L, Hunskaar S, Sykes D.

Assessment of bothersomeness and impact on quality of life of urinary incontinence in women in France, Germany, Spain and the UK. BJU Int. 2005 Oct; 96(6):831-8.

Voss S, Lose G, Papanicolaou S, Hunskaar S.

How do women cope with urinary incontinence? Results from a population based study of women in four European countries. Int Urogyn J (2003), S24.

Torgerson DJ, Sykes D, Puffer S, Brown P, Cooper C.

Pharmaceutical Treatment of Symptomatic Vertebral Fractures in Primary Care. Ann Rheum Dis 2004, 63:853-856.

Sykes D, Out HJ, Palmer SJ, van Loon J.

The cost-effectiveness of IVF in the UK: a comparison of three gonadotrophin treatments. Hum Reprod. 2001 Dec;16(12):2557-62.

Sykes D, Hunskaar S, et al.

Characteristics of female outpatients with urinary incontinence participating in a 6-month observational study in 14 European countries. Maturitas. 2005 Nov 30; 52 Suppl 2:S13-23.

Schiller JH, Tilden D, Aristides M, Lees M, Kielhorn A, Maniadakis N, Bhalla S.

Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Lung Cancer 43: 101-112 2004.

Puffer S, Torgerson DJ, Sykes D, Brown P, Cooper C.

Health Care Costs of Women with Symptomatic Vertebral Fracture. Bone, 2004; 35:383-86.

O'Donnell M, Lose G, Sykes D, Voss S, Hunskaar S.

Help-seeking behaviour and associated factors amongst women with urinary incontinence in France, Germany, Spain and the United Kingdom. European Urology 47 (2005) 385-92.

Nafees B, Stafford M, Bhalla S, Watkins J.

Health utilities in the UK for second line advanced non-small cell lung cancer (NSCLC) following prior chemotherapy Lung utility manuscript in press.

Monz B, Hunskaar S, Espuna M, Sykes D.

Patient-reported impact of urinary incontinence -- results from treatment seeking women in 14 European countries. Maturitas. 2005 Nov 30; 52 Suppl 2:S24-34.

Monz B, Hunskaar S, Espuna M, Sykes D.

A description of health care provision and access to treatment for women with urinary incontinence in Europe -- a five-country comparison. Maturitas. 2005 Nov 30;52 Suppl 2:S3-12.

Marin F, Cooper C, Sykes D.

Characterisation of patients with an inadequate clinical outcomes from osteoporosis therapy - the Observational Study of Severe Osteoporosis (OSSO). The Quarterly Journal of Medicine 2006 Aug 99(8):531-44.

Kanis J A, Borgstrom F, Johnell O, Oden A, Sykes D, B Borgstrom B.

Cost-effectiveness of Raloxifene in the UK -an economic evaluation based on the MORE study. Osteoporosis International, 2004, 15 (10): 802-19.

Hunskaar S, Lose G, Sykes D, Voss S.

The prevalence of urinary incontinence in women in four European countries. BJU Int. 2004 Feb; 93(3):324-30.

O'Donnell M, Lose G, Sykes D, Voss S, Hunskaar S.

Help-seeking behaviour and associated factors amongst women with urinary incontinence in France, Germany, Spain and the United Kingdom. European Urology 47 (2005) 385-92.

Nafees B, Stafford M, Bhalla S, Watkins J.

Health utilities in the UK for second line advanced non-small cell lung cancer (NSCLC) following prior chemotherapy Lung utility manuscript in press.

Monz B, Hunskaar S, Espuna M, Sykes D.

Patient-reported impact of urinary incontinence--results from treatment seeking women in 14 European countries. Maturitas. 2005 Nov 30;52 Suppl 2:S24-34.

Hampel C, Artibani W, Espu–a Pons M, Haab F, Jackson S, Romero J, Gavart S, Papanicolaou S.

Understanding the burden of stress urinary incontinence in Europe: A Qualitative Review of the Literature. European Urology (2004), 46:15-27.

Geitona M, Papanicolaou S, Aggelopoulos E, Ollandezos M, Kousoulakou C, Aggelopoulos E, Zaharakis K, Kakavas P, Karpouza B, Kesidou S, Bilanakis N, Papamichael E, Chaidemenos A, Chamogeorgakis T, Kyriopoulos J.

Treatment patterns and cost assessment of schizophrenia in Greece. Psychiatry 2007, 18:49-60.

Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S, Kyriopoulos I.

Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Annals of General Psychiatry, 2008, 7:16 (http://www.annals-general-psychiatry.com/content/7/1/16).

Finnern HW, Sykes D.

The hospital cost of vertebral fractures in the EU: estimates using national datasets. Osteoporos Int. 2003 Jun;14(5):429-36.

Ferguson B, Rice N, Sykes D, Aletras V, Eastwood A, Sheldon T, Sowden A, Place M, Posnett J,
Grilli R.

Hospital volume and health care outcomes, costs and patient access. Effective Health Care Bulletin, 1996; 2(8): 16.

Borgstrom F, Johnell O, Kanis J A, Oden A, Sykes D, B Jonsson B.

Cost-effectiveness of Raloxifene in Sweden - an economic evaluation based on the MORE study. Pharmacoeconomics, 2004 Vol 22(17):1153-65.

Aristides M, Bhalla S.

Determining patient preferences for improved chemotoxicity during treatment for advanced bladder cancer. European Journal of Cancer 2005.